Baculovirus display of single chain antibody (scFv) using a novel signal peptide

BMC Biotechnology

Volumn 10, Issue , 2010, Pages

  Kitidee, Kuntida ^a,b   Nangola, Sawitree ^a,b   Gonzalez, Gaëlle ^a   Boulanger, Pierre ^a   Tayapiwatana, Chatchai ^b   Hong, Saw See ^a  

^a UNIVERSITÉ LYON 1   (France)

^b CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID RESIDUES; BACULOVIRUS; CELL LYSATES; COEXPRESSED; EXTRACELLULAR MEDIUM; GENERAL METHOD; HIGH MOLECULAR WEIGHT; INFECTED CELLS; INHIBITORY EFFECT; INSECT CELLS; MATRIX PROTEINS; MEMBRANE-ASSOCIATED PROTEINS; N-MYRISTOYLATION; N-TERMINALS; REGULATORY PROTEIN; SIGNAL PEPTIDE; SINGLE CHAINS; SINGLE-CHAIN ANTIBODIES; VIRAL REPLICATION; VIRUS-LIKE PARTICLES;

AMINO ACIDS; ANTIGENS; ENZYME ACTIVITY; MOLECULES; MONOCLONAL ANTIBODIES; PEPTIDES; VIRUSES;

DISEASES;

AMINO ACID; BACULOVIRUS VECTOR; CD147 ANTIGEN; EPITOPE; GAG PROTEIN; MATRIX PROTEIN; MONOCLONAL ANTIBODY; PROTEIN P17; SIGNAL PEPTIDE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; P17 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS TYPE 1;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIGEN SPECIFICITY; ARTICLE; BACULOVIRUS; CARBOXY TERMINAL SEQUENCE; CELL LYSATE; CONTROLLED STUDY; INSECT CELL; MYRISTYLATION; NONHUMAN; PROTEIN EXPRESSION; VIRUS INFECTION; VIRUS LIKE AGENT; VIRUS RECOMBINANT; ANIMAL; ANTIBODY SPECIFICITY; BIOSYNTHESIS; CELL LINE; CYTOLOGY; GENE VECTOR; GENETICS; IMMUNOLOGY; INSECT;

HEXAPODA; HUMAN IMMUNODEFICIENCY VIRUS 1; VESICULAR STOMATITIS VIRUS;

ANIMALS; ANTIBODY SPECIFICITY; BACULOVIRIDAE; CELL LINE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENETIC VECTORS; HIV ANTIGENS; INSECTS; PROTEIN SORTING SIGNALS; SINGLE-CHAIN ANTIBODIES;

EID: 78349298326     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/1472-6750-10-80     Document Type: Article

References (66)

1. Pantophlet R, Burton DR. GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 2006, 24:739-769. 10.1146/annurev.immunol.24.021605.090557, 16551265.
2. Marasco WA. Intrabodies as antiviral agents. Curr Top Microbiol Immunol 2001, 260:247-270.
3. Marasco WA, Sui J. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol 2007, 25:1421-1434. 10.1038/nbt1363, 18066039.
4. Paillard F. Intrabodies to human immunodeficiency virus type 1. Hum Gene Ther 1999, 10:1425-1427. 10.1089/10430349950017752, 10395367.
5. Marasco WA, Haseltine WA, Chen SY. Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. Proc Natl Acad Sci USA 1993, 90:7889-7893. 10.1073/pnas.90.16.7889, 47248, 8356098.
6. Tewari D, Goldstein SL, Notkins AL, Zhou P. cDNA encoding a single-chain antibody to HIV p17 with cytoplasmic or nuclear retention signals inhibits HIV-1 replication. J Immunol 1998, 161:2642-2647.
7. Maciejewski JP, Weichold FF, Young NS, Cara A, Zella D, Reitz MSJ, Gallo RC. Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection in vitro. Nat Med 1995, 1:667-673. 10.1038/nm0795-667, 7585149.
8. Bai J, Sui J, Zhu RY, Tallarico AS, Gennari F, Zhang D, Marasco WA. Inhibition of Tat-mediated transactivation and HIV-1 replication by human anti-hCyclinT1 intrabodies. J Biol Chem 2003, 278:1433-1442. 10.1074/jbc.M208297200, 12401780.
9. Marasco WA, LaVecchio J, Winkler A. Human anti-HIV-1 tat sFv intrabodies for gene therapy of advanced HIV-1-infection and AIDS. J Immunol Methods 1999, 231:223-238. 10.1016/S0022-1759(99)00159-3, 10648940.
10. Goncalves J, Silva F, Freitas-Vieira A, Santa-Marta M, Malhó R, Yang X, Gabuzda D, Barbas C. Functional neutralization of HIV-1 Vif protein by intracellular immunization inhibits reverse transcription and viral replication. J Biol Chem 2002, 277:32036-32045. 10.1074/jbc.M201906200, 12039955.
11. Aires da Silva F, Santa-Marta M, Freitas-Vieira A, Mascarenhas P, Barahona I, Moniz-Pereira J, Gabuzda D, J G. Camelized rabbit-derived VH single-domain intrabodies against Vif strongly neutralize HIV-1 infectivity. J Mol Biol 2004, 340:525-542. 10.1016/j.jmb.2004.04.062, 15210352.
12. Slack J, Arif BM. The baculoviruses occlusion-derived virus: virion structure and function. Adv Virus Res 2007, 69:99-165. 10.1016/S0065-3527(06)69003-9, 17222693.
13. Possee RD. Baculoviruses as expression vectors. Curr Opin Biotech 1997, 8:569-572. 10.1016/S0958-1669(97)80030-4, 9353228.
14. Hu YC. Baculoviral vectors for gene delivery: a review. Curr Gene Ther 2008, 8:(1):54-65.
15. Kost TA, Condreay JP, Jarvis DL. Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat Biotechnol 2005, 23:567-575. 10.1038/nbt1095, 15877075.
16. Mäkelä AR, Oker-Blom C. The baculovirus display technology--an evolving instrument for molecular screening and drug delivery. Comb Chem High Throughput Screen 2008, 11:86-98. 10.2174/138620708783744525, 18336202.
17. Mäkelä AR, Oker-Blom C. Baculovirus display: a multifunctional technology for gene delivery and eukaryotic library development. Adv Virus Res 2006, 68:91-112. 10.1016/S0065-3527(06)68003-2, 16997010.
18. Mottershead DG, Alfthan K, Ojala K, Takkinen K, Oker-Blom C. Baculoviral display of functional scFv and synthetic IgG-binding domains. Biochem Biophys Res Commun 2000, 275:84-90. 10.1006/bbrc.2000.3264, 10944446.
19. Ojala K, Mottershead DG, Suokko A, Oker-Blom C. Specific binding of baculoviruses displaying gp64 fusion proteins to mammalian cells. Biochem Biophys Res Commun 2001, 284:777-784. 10.1006/bbrc.2001.5048, 11396970.
20. Chapple SD, Jones IM. Non-polar distribution of green fluorescent protein on the surface of Autographa californica nucleopolyhedrovirus using a heterologous membrane anchor. J Biotechnol 2002, 95:269-275. 10.1016/S0168-1656(02)00023-8, 12007867.
21. Ojala K, Koski J, Ernst W, Grabherr R, Jones I, O-B C. Improved display of synthetic IgG-binding domains on the baculovirus surface. Technol Cancer Res Treat 2004, 3:77-84.
22. Robert-Hebmann V, Emiliani S, Jean F, Resnicoff M, Traincard F, Devaux C. Clonal analysis of murine B cell response to the human immunodeficiency virus type 1 (HIV-1)-gag p17 and p25 antigens. Mol Immunol 1992, 29:729-738. 10.1016/0161-5890(92)90183-X, 1376412.
23. Robert-Hebmann V, Emiliani S, Resnicoff M, Jean F, Devaux C. Subtyping of human immunodeficiency virus isolates with a panel of monoclonal antibodies: identification of conserved and divergent epitopes on p17 and p25 core proteins. Mol Immunol 1992, 29:1175-1183. 10.1016/0161-5890(92)90053-Z, 1382219.
24. Carrière C, Gay B, Chazal N, Morin N, Boulanger P. Sequence requirement for encapsidation of deletion mutants and chimeras of human immunodeficiency virus type 1 Gag precursor into retrovirus-like particles. J Virol 1995, 69:2366-2377. 188909, 7884882.
25. Fiorentini S, Marini E, Caracciolo S, Caruso A. Functions of the HIV-1 matrix protein p17. New Microbiol 2006, 29:1-10.
26. Wilk T, Gross I, Gowen BE, Rutten T, de Haas F, Welker R, Kräusslich H-G, Boulanger P, Fuller SD. Organization of immature human immunodeficiency virus type 1. J Virol 2001, 75:759-771. 10.1128/JVI.75.2.759-771.2001, 113972, 11134289.
27. Boulanger P, Jones I. Morphogenesis and maturation of Retroviruses. Use of heterologous expression systems to study retroviral morphogenesis. Curr Topics Microbiol Immunol 1996, 214:237-260. Berlin, Heidelberg, New York: Springer-Verlag, Kräusslich H-G.
28. Chazal N, Carrière C, Gay B, Boulanger P. Phenotypic characterization of insertion mutants of the human immunodeficiency virus type 1 Gag precursor expressed in recombinant baculovirus-infected cells. J Virol 1994, 68:111-122. 236270, 8254720.
29. Chazal N, Gay B, Carrière C, Tournier J, Boulanger P. Human immunodeficiency virus type 1 MAp17 deletion mutants expressed in baculovirus-infected cells: cis and trans effects on the Gag precursor assembly pathway. J Virol 1995, 69:365-375. 188584, 7983731.
30. Hong SS, Boulanger P. Self-assembly-defective dominant mutants of HIV-1 Gag phenotypically expressed in baculovirus-infected cells. J Virol 1993, 67:2787-2798. 237603, 8474175.
31. Royer M, Cerutti M, Gay B, Hong SS, Devauchelle G, Boulanger P. Functional domains of HIV-1 gag-polyprotein expressed in baculovirus-infected cells. Virology 1991, 184:417-422. 10.1016/0042-6822(91)90861-5, 1871977.
32. Royer M, Hong SS, Gay B, Cerutti M, Boulanger P. Expression and extracellular release of human immunodeficiency virus type 1 Gag precursors by recombinant baculovirus-infected cells. J Virol 1992, 66:3230-3235. 241093, 1560545.
33. Bouyac M, Courcoul M, Bertoia G, Baudat Y, Gabuzda D, Blanc D, Chazal N, Boulanger P, Vigne R, Spire B. Human immunodeficiency virus type 1 Vif protein binds to the Pr55GAG precursor. J Virol 1997, 71:9358-9365. 230239, 9371595.
34. DaFonseca S, Coric P, Gay B, Hong SS, Bouaziz S, Boulanger P. The inhibition of assembly of HIV-1 virus-like particles by 3-O-(3',3'-dimethylsuccinyl) betulinic acid (DSB) is counteracted by Vif and requires its Zinc-binding domain. Virol J 2008, 5:162. 10.1186/1743-422X-5-162, 2628355, 19105849.
35. Huvent I, Hong SS, Fournier C, Gay B, Tournier J, Carriere C, Courcoul M, Vigne R, Spire B, Boulanger P. Interaction and co-encapsidation of HIV-1 Vif and Gag recombinant proteins. J Gen Virol 1998, 79:1069-1081.
36. Bardy M, Gay B, Pébernard S, Chazal N, Courcoul M, Vigne R, Decroly E, Boulanger P. Interaction of human immunodeficiency virus type 1 Vif with Gag and Gag-Pol precursors: co-encapsidation and interference with viral protease-mediated Gag processing. J Gen Virol 2001, 82:2719-2733.
37. Royer M, Bardy M, Gay B, Tournier J, Boulanger P. Proteolytic activity in vivo and encapsidation of recombinant HIV-1 proteinase expressed in baculovirus-infected cells. J Gen Virol 1997, 78:131-142.
38. Intasai N, Tragoolpua K, Pingmuang P, Khunkaewla P, Moonsom S, Kasinrerk W, Lieber A, Tayapiwatana C. Potent inhibition of OKT3-induced T cell proliferation and suppression of CD147 cell surface expression in HeLa cells by scFv-M6-1B9. Immunobiology 2009, 214:410-421.
39. Tragoolpua K, Intasai N, Kasinrerk W, Mai S, Yuan Y, Tayapiwatana C. Generation of functional scFv intrabody to abate the expression of CD147 surface molecule of 293A cells. BMC Biotechnol 2008, 8:5. 10.1186/1472-6750-8-5, 2258298, 18226275.
40. DaFonseca S, Blommaert A, Coric P, Hong SS, Bouaziz S, Boulanger P. The 3-O-(3',3'-dimethylsuccinyl) derivative of betulinic acid (DSB) inhibits the assembly of virus-like particles in HIV-1 Gag precursor-expressing cells. Antiviral Ther 2007, 12:1185-1203.
41. Granio O, Porcherot M, Corjon S, Kitidee K, Henning P, Eljaafari A, Cimarelli A, Lindholm L, Miossec P, Boulanger P, et al. Improved adenovirus type 5 vector-mediated transduction of resistant cells by piggybacking on CAR-pseudotyped baculovirus. J Virol 2009, 83:6048-6066. 10.1128/JVI.00012-09, 2687387, 19357170.
42. Fournier C, Cortay J-C, Carbonnelle C, Ehresmann C, Marquet R, Boulanger P. The HIV-1 Nef protein enhances the affinity of reverse transcriptase for RNA in vitro. Virus Genes 2002, 25:255-269. 10.1023/A:1020971823562, 12881637.
43. Saurya S, Lichtenstein Z, Karpas A. Characterization of gag gene of plasma HIV type 1 in combination therapy-treated AIDS patients with high viral load and stable CD4+ T cell counts. AIDS Res Hum Retroviruses 2003, 19:73-76. 10.1089/08892220360473998, 12596727.
44. Boudin M-L, Rigolet M, Lemay P, Galibert F, Boulanger P. Biochemical and genetical characterization of a fiber-defective temperature-sensitive mutant of type 2 adenovirus. EMBO J 1983, 2:1921-1927. 555389, 6571701.
45. Caillet-Boudin M-L, Lemay P, Boulanger P. Functional and structural effects of an Ala-to-Val mutation in the adenovirus type 2 fibre. J Mol Biol 1991, 217:477-486. 10.1016/0022-2836(91)90751-Q, 1994035.
46. LeDuc PR, Whiteley EM, Bao G, Betenbaugh MJ. Investigating the secretory pathway of the baculovirus-insect cell system using a secretory green fluorescent protein. Biotechnol Prog 2000, 16:716-723. 10.1021/bp0001112, 11027162.
47. Demangel C, Zhouc J, Chood ABH, Shoebridge G, Hallidaye GM, Britton WJ. Single chain antibody fragments for the selective targeting of antigens to dendritic cells. Mol Immunol 2005, 42:979-985. 10.1016/j.molimm.2004.09.034, 15829289.
48. Peipp M, Saul D, Barbin K, Bruenke J, Zunino SJ, Niederweis M, Fey GH. Efficient eukaryotic expression of fluorescent scFv fusion proteins directed against CD antigens for FACS applications. J Immunol Methods 2004, 285:265-280. 10.1016/j.jim.2003.12.001, 14980440.
49. Thomas JE, Massalski PR, Harrison BD. Production of monoclonal antibodies to African cassava mosaic virus and differences in their reactivities with other whitefly-transmitted geminiviruses. J gen Virol 1986, 67:2739-2748.
50. Reavy B, Ziegler A, Diplexcito J, Macintosh SM, Torrance L, Mayo M. Expression of functional recombinant antibody molecules in insect cell expression systems. Protein Expr Purif 2000, 18:221-228. 10.1006/prep.1999.1191, 10686153.
51. Laroche Y, Demaeyer M, Stassen J-M, Gansemans Y, Demarsin E, Matthyssens G, Collen D, Holvoet P. Characterization of a recombinant single-chain molecule comprising the variable domains of a monoclonal antibody specific for human fibrin fragment D-dimer. J Biol Chem 1991, 266:16343-16349.
52. Grabherr R, Ernst W, Oker-Blom C, Jones I. Developments in the use of baculoviruses for the surface display of complex eukaryotic proteins. Trends Biotechnol 2001, 19:231-236. 10.1016/S0167-7799(01)01610-9, 11356285.
53. Hu YC. Baculovirus vectors for gene therapy. Adv Virus Res 2006, 68:287-320. 10.1016/S0065-3527(06)68008-1, 16997015.
54. Loisel TP, Ansanay H, St-Onge S, Gay B, Boulanger P, Strosberg AD, Marullo S, Bouvier M. Recovery of homogeneous and functional beta 2-adrenergic receptors from extracellular baculovirus particles. Nat Biotechnol 1997, 15:1300-1304. 10.1038/nbt1197-1300, 9359116.
55. Belyakov IM, Berzofsky JA. Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccine. Immunity 2004, 20:247-253. 10.1016/S1074-7613(04)00053-6, 15030769.
56. De Francesco MA, Baronio M, Fiorentini S, Signorini C, Bonfanti C, Poiesi C, Popovic M, Grassi M, Garrafa E, Bozzo L, et al. HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor. Proc Natl Acad Sci USA 2002, 99:9972-9977. 10.1073/pnas.142274699, 126609, 12105273.
57. Matsudaira H, Asakura T, Aoki K, Searashi Y, Matsuura T, Nakajima H, Tajiri H, Ohkawa K. Target chemotherapy of anti-CD147 antibody-labeled liposome encapsulated GSH-DXR conjugate on CD147 highly expressed carcinoma cells. Int J Oncol 2010, 36:77-83.
58. Du Z-M, Hu C-F, Shao Q, Huang M-Y, Kou C-W, Zhu X-F, Zeng Y-X, Shao J-Y. Upregulation of caveolin-1 and CD147 expression in nasopharyngeal carcinoma enhanced tumor cell migration and correlated with poor prognosis of the patients. Int J Cancer 2009, 125:1832-1841. 10.1002/ijc.24531, 19582878.
59. Han ZD, Bi XC, Qin WJ, He HC, Dai QS, Zou J, Ye YK, Liang YX, Zeng GH, Chen ZN, et al. CD147 expression indicates unfavourable prognosis in prostate cancer. Pathol Oncol Res 2009, 15:369-374. 10.1007/s12253-008-9131-z, 19048397.
60. Tan H, Ye K, Wang Z, Tang H. CD147 expression as a significant prognostic factor in differentiated thyroid carcinoma. Transl Res 2008, 152:143-149. 10.1016/j.trsl.2008.07.005, 18774544.
61. Yoon YW, Kwon HM, Hwang KC, Choi EY, Hong BK, Kim D, Kim HS, Cho SH, Song KS, Sangiorgi G. Upstream regulation of matrix metalloproteinase by EMMPRIN; extracellular matrix metalloproteinase inducer in advanced atherosclerotic plaque. Atherosclerosis 2005, 180:37-44. 10.1016/j.atherosclerosis.2004.11.021, 15823273.
62. Gou X, Ru Q, Zhang H, Chen Y, Li L, Yang H, Xing J, Chen Z. HAb18G/CD147 inhibits starvation-induced autophagy in human hepatoma cell SMMC7721 with an involvement of Beclin 1 down-regulation. Cancer Sci 2009, 100:837-843. 10.1111/j.1349-7006.2009.01113.x, 19298604.
63. Peden K, Emerman M, Montagnier L. Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI. Virology 1991, 185:661-672. 10.1016/0042-6822(91)90537-L, 1683726.
64. Sanchez-Merino V, Nie S, Luzuriaga K. HIV-1-specific CD8+ T cell responses and viral evolution in women and infants. J Immunol 2005, 175:6976-6986.
65. Nagai H, Wada K, Morishita T, Utsumi M, Nishiyama Y, Kaneda T. New estimation method for highly sensitive quantitation of human immunodeficiency virus type 1 DNA and its application. J Virol Methods 2005, 124:157-165. 10.1016/j.jviromet.2004.11.025, 15664064.
66. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 1986, 59:284-291. 253077, 3016298.